VEGF Polyclonal Antibody, FITC Conjugated
Cat# bs-0279R-FITC
Size : 100ul
Marca : Bioss
VEGF Polyclonal Antibody, FITC Conjugated
Applications
Reactivity
Overview | |
Catalog # | bs-0279R-FITC |
Product Name | VEGF Polyclonal Antibody, FITC Conjugated |
Applications | WB, FCM, IF(IHC-P), IF(IHC-F) |
Reactivity | Human, Mouse, Rat, Pig, Goat, Others |
Specifications | |
Conjugation | FITC |
Host | Rabbit |
Source | KLH conjugated synthetic peptide derived from human VEGF |
Immunogen Range | 27-120/232 |
Clonality | Polyclonal |
Isotype | IgG |
Concentration | 1ug/ul |
Purification | Purified by Protein A. |
Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
Storage Condition | Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
Target | |
Gene ID | 7422 |
Swiss Prot | P15692 |
Subcellular location | Secreted |
Synonyms | VPF; VEGF; MVCD1; Vascular endothelial growth factor A; VEGF-A; Vascular permeability factor; VEGFA |
Background | Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth. |
Application Dilution | |
WB | 1:300-5000 |
FCM | 1:20-100 |
IF(IHC-P) | 1:50-200 |
IF(IHC-F) | 1:50-200 |